We have previously demonstrated that transforming growth factor-b (TGF-b) and pro-in¯ammatory cytokines, such as tumor necrosis factor-a (TNF-a) or interleukin-1b, synergistically enhance the expression of type VII collagen gene (COL7A1) in human dermal ®broblasts in culture (Mauviel et al., 1994) . Recently, we identi®ed a SMAD-containing complex, rapidly induced by TGF-b and binding the region [7496/7444] of the COL7A1 promoter, responsible for COL7A1 gene transactivation (Vindevoghel et al., 1998a) . In this report, we demonstrate that TGF-b and TNF-a response elements are distinct entities within the COL7A1 promoter. In particular, we demonstrate that the TNFa eect is mediated by NF-kB1/RelA (p50/p65) and RelA/RelA (p65/p65) NF-kB complexes binding the TNF-a response element (TaRE) located in the region [7252/7230], with RelA acting as the transcriptional activator. Finally, we provide de®nitive evidence for the role of both TGF-b and TNF-a response elements as enhancer sequences, functioning in the context of a heterologous promoter in an additive manner in response to TGF-b and TNF-a. This study provides the ®rst identi®cation of a functional interaction between the two immediate-early transcription factors, SMAD and NFkB, to activate the expression of an extracellular matrixrelated gene, COL7A1.
Introduction
Type VII collagen is the predominant, if not the exclusive, component of the anchoring ®brils, attachment structures stabilizing the association of the cutaneous basement membrane to the underlying dermis (reviewed in Burgeson, 1993; Christiano and Uitto, 1996) . In the skin, type VII collagen is synthesized by both dermal ®broblasts and epidermal keratinocytes. Alterations in the type VII collagen protein structure or lack of its expression due to mutations in the corresponding gene COL7A1 are the hallmark of dystrophic epidermolysis bullosa, a mechano-bullous skin disease characterized by extreme fragility of the skin and leading to development of sub-lamina densa blisters (reviewed in Christiano and Uitto, 1996) .
We have previously shown that pro-in¯ammatory cytokines, such as TNF-a and IL-1, as well as TGF-b, are potent inducers of COL7A1 expression (Mauviel et al., 1994) . The regulation of COL7A1 by cytokines and growth factors diers from that of other collagens, as exempli®ed by type I collagen. Speci®cally, we previously demonstrated that TGF-b has an additive, if not synergistic, eect with pro-in¯ammatory cytokines, such as IL-1 or TNF-a, on type VII collagen gene expression, as measured at both protein and mRNA levels (Mauviel et al., 1994) . In contrast, the eects of TGF-b and TNF-a on type I collagen gene expression are antagonistic, TGF-b being a powerful activator of type I collagen gene promoters (both COL1A1 and COL1A2) while TNF-a exerts an inhibitory eect (Varga et al., 1987; Inagaki et al., 1995; Chung et al., 1996) .
Recently, we have demonstrated that TGF-b upregulation of COL7A1 gene expression occurs at the transcriptional level and we identi®ed the TGF-b responsive region of the COL7A1 promoter as a target of the SMAD signaling pathway (Vindevoghel et al., 1998a) . Speci®cally, we have shown that a SMAD3-containing complex rapidly forms with the COL7A1 promoter in response to TGF-b. The resulting gene transactivation occurs in a SMAD4-dependent manner (Vindevoghel et al., 1998b) .
In this study, we have examined whether the additive eect of TGF-b with TNF-a on type VII collagen gene expression is exerted at the transcriptional level by activation of the corresponding promoter. We demonstrate that the two cytokines independently activate the COL7A1 promoter through distinct response elements, TGF-b acting via direct SMAD binding to the 7496/7444 region of the promoter, whereas TNF-a eect is mediated by binding of NF-kB1/RelA NF-kB to a cis-element located between nucleotides 7252 and 7230, i.e. approximately 200 bp downstream from the TGF-b response element. These data represent the ®rst demonstration of additive transcriptional activity of two immediate-early transcription factors, SMAD and NF-kB, in the context of the activation of an extracellular matrix gene, COL7A1, by cytokines often characterized as antagonistic to each other in a number of experimental systems.
Results

TNF-a and TGF-b exert an additive eect on the COL7A1 promoter
To determine whether the additive eect of TGF-b and TNF-a on COL7A1 gene expression, as determined at both the mRNA and protein levels (Mauviel et al., 1994) , was exerted, at least in part, at the transcriptional level through activation of the corresponding promoter, transient cell transfection experiments were performed in human dermal ®broblast cultures. These studies utilized a COL7A1 promoter/CAT reporter gene construct containing 722 bp of 5' end regulatory sequences of the human COL7A1 gene . As shown in Figure 1 , TGF-b and TNF-a both enhanced COL7A1 promoter activity (6.8-and 3.6-fold, respectively). An additive eect was observed (13.3-fold) when the two cytokines were added simultaneously to the ®broblast culture medium. These data establish that both cytokines exert their enhancing activity on COL7A1 gene expression, at least in part, at the transcriptional level.
Delineation of the TNF-a responsive region within the COL7A1 promoter
We have recently demonstrated that the TGF-b responsive sequences reside between nucleotides 7496 and 7444, relative to the transcription start site of the COL7A1 gene (Vindevoghel et al., 1998a) . To characterize the TNF-a responsive region of the COL7A1 promoter, ®broblast cultures were transfected with a series of 5' end deletion COL7A1 promoter/CAT constructs .
Cells were subsequently treated with TNF-a for 40 h, at which point CAT activity was determined. As shown in Figure 2 , a stimulatory eect of TNF-a, varying from 2.5 ± 4.7-fold, was observed with constructs containing at least 7396 bp of COL7A1 5' regulatory sequences. TNF-a responsiveness was totally abolished by further 5' deletion to position 7230 of the promoter, indicating that the TNF-a responsive sequences are located between nucleotides 7396 and 7230.
The 7271/7201 COL7A1 promoter fragment binds a rapidly-induced, TNF-a-responsive nuclear factor
The transfection experiments described above undoubtedly identi®ed the TNF-a responsive region of the COL7A1 promoter as being distinct from the recently characterized TGF-b response element (Vindevoghel et al., 1998a) . A schematic representation is provided in Figure 3a , indicating the distinct growth factor/ cytokine responsive regions. To determine whether the region of COL7A1 promoter conferring TNF-a responsiveness contained TNF-a-speci®c cis-elements, electrophoretic mobility shift assays (EMSAs) were performed with two overlapping DNA probes covering the entire region between nucleotides 7410 and 7201 (see Figure 3a) . As shown in Figure 3b , no dierence in the binding pattern of nuclear extracts from control or TNF-a-treated ®broblasts could be observed with the probe spanning the region 7410/7300. On the other hand, a speci®c TNF-a-induced band with retarded mobility was observed with the 7319/7201 probe at 1 h following TNF-a addition to the ®broblast medium. Time-course experiments indicated a progressive enhancement of DNA binding activity, detectable as early as 5 min after TNF-a addition, with a maximal intensity between 15 and 60 min (Figure 3c ). The retarded DNA-protein complex appeared to consist of two closely migrating bands.
Figure 1 TNF-a and TGF-b exert an additive eect on the COL7A1 promoter. Con¯uent ®broblast cultures were transfected with the 7722COL7A1/CAT construct of the human COL7A1 promoter by the calcium phosphate/DNA co-precipitation procedure, as described in Materials and methods. After glycerol shock, the cultures were incubated in fresh medium containing 1% fetal calf serum. TNF-a and/or TGF-b (10 ng/ml) were added to the medium 4 h later. After 40 h of incubation, cell extracts were assayed for CAT activity with [ 2 Delineation of the TNF-a responsive region within the COL7A1 promoter. Con¯uent ®broblast cultures were transfected with various 5' deletion/CAT constructs of the human COL7A1 promoter by the calcium phosphate/DNA co-precipitation procedure, as described in Materials and methods. After glycerol shock, the cultures were incubated in fresh medium containing 1% fetal calf serum, without (7) or with (+) TNF-a (10 ng/ml) added to the medium 4 h later. After 40 h of incubation, cell extracts were assayed for CAT activity with [ Binding of TNF-a-speci®c nuclear proteins to the 7271/7201 COL7A1 promoter fragment is competed by a consensus NF-kB oligonucleotide Sequence analysis of the 7271/7201 region revealed a potential NF-kB binding site at position 7237/7227. This observation, together with the rapid induction of the DNA/protein complex by TNF-a, prompted us to perform competition experiments with unlabeled oligonucleotides, in order to address the speci®city of the TNF-a-induced band. As shown in Figure 4 , addition of 20-and 60-fold excess of consensus NFkB oligonucleotide dose-dependently diminished the TNF-a-speci®c DNA/protein complex forming with the 7271/7201 probe, whereas a 60-fold excess AP-1 oligonucleotide had no eect on the same complex. These data suggested that the potential NF-kB binding site identi®ed by sequence analysis may, indeed, be functional and responsible for the TNF-a-induced complex.
NF-kB1 and Re1A NF-kB family members bind the TNF-a response element
The next set of experiments was designed to identify the protein(s) present in the TNF-a-induced complex. For this purpose, gel supershift assays were performed with a panel of antibodies directed against either NF-AT or various members of the NF-kB family of transcription factors, using either the 7271/7201 Two overlapping oligonucleotides spanning the region 7410 to 7201 of COL7A1 promoter, were used as probes in EMSA experiments to study their ability to bind transcription factors in response to TNF-a. The nuclear extracts were isolated from untreated con¯uent ®broblast cultures (0), or at various time points (1, 3 and 24 h) after TNF-a stimulation. Note the appearance of a TNF-a speci®c complex with the 7319/7201 probe (bracket). (c) Dermal ®broblast cultures were incubated with 10 ng/ml of TNF-a for various time points (0 ± 60 min) prior to preparation of nuclear extracts. The radiolabeled 7319/7201 fragment was used as a probe. Note the rapid appearance of the TNF-a-speci®c complex. (d) EMSA with nuclear extracts from control and TNF-a-treated (30 min) ®broblast cultures using either 7319/7248 or 7271/7201 COL7A1 promoter fragments as probes. The TNF-a-speci®c complex only forms with the 7271/7201 probe probe (Figure 5a ), or a shorter fragment, 7247/7216, also containing the NF-kB site (Figure 5b ). Similar supershifting patterns were observed with both probes. Speci®cally, a pan-NF-AT failed to alter the TNF-ainduced band. In contrast, the NF-kB1 antibody supershifted the lower band of the doublet, whereas the RelA antibody was able to supershift both components of the doublet induced by TNF-a. Neither the NF-kB2 nor the RelB and Rel antibodies could alter the TNF-a speci®c bands. Together, these data suggest that the lower band of the doublet contains both NF-kB1 and RelA NF-kB proteins, whereas the upper band likely represents RelA homodimers, consistent with previously characterized NF-kB complexes induced by TNF-a in dermal ®broblast cultures . Utilization of the shorter DNA probe 7247/7216 (Figure 5b ) resulted in enhanced ecacy of the binding and reduced number of additional, faster migrating bands observed in nuclear extracts from both control and TNF-a-treated ®broblasts when using larger probes ( Figures 3, 4 and 5a).
Point mutations within the NF-kB binding site of the COL7A1 promoter abolish the TNF-a responsiveness Our next aim was to determine whether the NF-kB site was functional in the context of the COL7A1 promoter. For this purpose, novel deletion constructs were generated, with a 5' end at position 7252, keeping the NF-kB intact or mutating it (construct 7252 m) to render it incapable of binding NF-kB proteins (EMSAs not shown). Results of the transient cell transfections, shown in Figure 6 , indicate that removal of the region between nucleotides 7396 and 7252 does not alter TNF-a responsiveness, the latter being lost after further deletion to 7230. These ®ndings restrict the TNF-a responsive region to the fragment 7252/7230, a result which is in total agreement with the EMSA data presented above.
In addition, it should be noted that functional mutations of the 7237/7227 NF-kB site (GGGAATTCCC to AAGAATTCAT; construct 7252 mCOL7A1/CAT) totally abolished the responsiveness of the CAT construct to TNF-a (Figure 6 ), attesting to its role as an element essential for TNF-a response of the COL7A1 promoter.
Eects of NF-kB1 or RelA over-expression on COL7A1 promoter activity in transient cell transfection experiments
To determine the role played by NF-kB1 and RelA in mediating TNF-a eect on COL7A1 promoter activity, Figure 5 NF-kB1 (p50) and RelA (p65) NF-kB family members bind the TaRE. EMSAs were performed using either the 7271/ 7201 (a) or 7247/7216 (b) COL7A1 promoter fragments as probes. CTL, extracts from control cultures; TNF-a, extracts from TNF-a-treated ®broblast cultures. Supershift experiments were performed with antibodies speci®c for several Rel family members and with an antibody cross-reactive with all NF-AT family members (1 ml of each antibody preparation incubated overnight with the nuclear extracts prior to the binding reaction). Only NF-kB1 and RelA antibodies supershift the TNF-a-speci®c complex. The faint band seen in (a) with the NF-AT and NF-kB2 antibodies is non speci®c, as it is also obtained in the absence of nuclear extracts in the binding reaction (not shown) Figure 4 Binding of TNF-a-speci®c nuclear proteins to the 7271/7201 COL7A1 promoter fragment is competed by a consensus NF-kB oligonucleotide. EMSAs were performed using the 7271/7201 COL7A1 promoter fragment as a probe. CTL, nuclear extracts from control ®broblast cultures; TNF-a, nuclear extracts from ®broblast cultures treated with 10 ng/ml of TNF-a for 30 min. NF-kB and AP-1 consensus oligonucleotides (22 bp) were used as competitors, as indicated. Note the ecient competition of the TNF-a-speci®c complex by the NF-kB oligonucleotide co-transfection experiments of the minimal COL7A1 promoter responsive construct (7252COL7A1/CAT) with NF-kB1 and RelA expression vectors were performed. As shown in Figure 7 (left panel), NFkB1 overexpression had little, if any, activity on either basal or TNF-a-induced CAT activity. In contrast, RelA overexpression was able to achieve a promoter activation similar to that obtained with TNF-a stimulation. In addition, no further activation of the promoter by TNF-a could be achieved in RelAtransfected cells, suggesting that RelA is the transcription factor responsible for TNF-a eect on COL7A1 promoter activity. The transcriptional eect of RelA was mediated through the NF-kB site identi®ed above, as the 7252mCOL7A1/CAT construct containing an inactivated NF-kB site did not respond to RelA (Figure 7, right panel) . Collectively, these data suggest that RelA is the transcription factor responsible for TNF-a eect on COL7A1 promoter activity, through rapid and speci®c binding to the NF-kB binding site identi®ed in the region 7252/7230 of the COL7A1 promoter.
Combined tandem repeats of both TGF-b and TNF-a response elements confer cytokine additivity to a heterologous promoter in transient cell transfection experiments
First, we aimed to determine the functionality of both the NF-kB element and the previously identi®ed 7496/ 7444 SMAD binding sequence (SBS) corresponding to the TGF-b response element (Vindevoghel et al., 1998a,b) outside the context of the COL7A1 promoter. For this purpose, a quadruple tandem repeat of a 22 bp oligonucleotide containing the COL7A1 NF-kB site identi®ed above and a double tandem repeat of the SBS were cloned upstream of the thymidine kinase promoter, in the context of the plasmid pBLCAT5, either as wild-type, unaltered sequences, or as non functional mutants. As shown in Figure 8a , four copies of the COL7A1 NF-kB site ((NF-kB) 4 -TK/CAT) conferred TNF-a but not TGF-b responsiveness to the otherwise unresponsive pBLCAT5 plasmid (not shown). This activation by TNF-a could be abolished by functional inactivation of the NF-kB site (not shown). (SBS) 2 -TK/CAT, on the other hand, was only inducible by TGF-b (Figure 8b) .
Next, both elements were cloned in combination as tandem repeats upstream of the TK promoter into pBLCAT5, either as wild-type or mutant sequences, to create the constructs (NF-kB) 4 -(SBS) 2 -TK/CAT and (NF-kBmut) 4 -(SBSmut) 2 -TK/CAT. As shown in Figure  8c , (NF-kB) 4 -(SBS) 2 -TK/CAT, not only responded to either one of the cytokines alone, but TGF-b and TNF-a exerted their additive eects, as observed in the context of the COL7A1 promoter . The eect of either cytokine, alone or in combination, was abolished when a functional mutation was introduced into its corresponding response element repeats (NF-kBmut) 4 -(SBSmut) 2 -TK/CAT, (Figure 8d ). Together, these data attest for the fact that TGF-b and TNF-a exert their eect on (NF-kB) 4 -(SBS) 2 -TK/CAT through the SBS and NF-kB repeats, respectively.
Discussion
Type VII collagen assembly into anchoring ®brils provides the structural integrity to the stable attachment of the cutaneous basement membrane to the underlying dermis. Pathological conditions aecting type VII collagen deposition, such as structural mutations in the COL7A1 gene (reviewed in Christiano and , are known as dystrophic forms of epidermolysis bullosa (DEB). Other studies have also suggested that de®cient expression of type VII collagen Con¯uent ®broblast cultures were transfected with either 7252 or 7252mCOL7A1/CAT constructs, together with either a NFkB1 or a RelA expression vector, alone or in combination. After glycerol shock, the cultures were incubated in fresh medium containing 1% fetal calf serum for 4 h, prior to TNF-a addition (10 ng/ml). Cell extract were assayed for CAT activity with may also occur at the pre-translational level (Iwasaki et al., 1993) . Therefore, in certain situations, such as in the dominant forms of DEB, pharmacologic upregulation of COL7A1 gene expression may be helpful in reducing blister formation. Understanding of the molecular aspects of COL7A1 gene regulation is an essential step toward the elaboration of such pharmacologic approaches.
In this study, we have demonstrated that TGF-b and TNF-a utilize strikingly dierent pathways to activate the COL7A1 promoter in an additive manner. Interestingly, both cytokines act rapidly, through the use of immediate-early transcription factors, SMAD and NF-kB, whose translocation to the nucleus occurs within minutes following binding of the cytokines to their membrane receptors. These results are remarkable in demonstrating that a gene encoding a structural protein, COL7A1, with a half-life estimated to be of approximately 6 months (Woodley et al., 1990) , can be regulated by rapid transcriptional events.
The additive eect of TGF-b and TNF-a occurring at the transcriptional level is somewhat unique, as these cytokines are considered to be antagonistic in most of their activities. In the context of extracellular matrix (ECM) remodeling, TGF-b promotes ECM accumulation, by both reducing the expression of metalloproteinases and by increasing the synthesis of ECM components (Mauviel et al., 1993) . In contrast, in¯ammatory cytokines such as IL-1 and TNF-a induce metalloproteinases gene expression and inhibit ECM synthesis (reviewed in Mauviel and Uitto, 1993) . We have recently demonstrated that TGF-b and TNFa exert their antagonistic activities on COL1A2 gene promoter through adjacent cis-elements (Chung et al., 1996; Kouba et al., 1997) . Antagonism between TGF-b and TNF-a has been described on NF1/CTF-1-mediated transcription (Alevizopoulos and Mermod, 1996) . Speci®cally, in the latter case, a single element, CTF-1, is the molecular target for mutually antagonistic regulation by TGF-b and TNF-a.
The stimulatory eect of TNF-a, and its additive eect with TGF-b, on COL7A1 gene transcription is remarkable, as it contrasts its known inhibitory activity on the expression of ®bril collagen genes, such as COL1A1, COL1A2 or COL3A1 (reviewed in Mauviel and Uitto, 1993) . Contrary to these ®brillar collagens whose excessive deposition leads to pathologic conditions such as hypertrophic scars, keloids, or ®brosis in general, disease states associated with type VII collagen result from decreased or absent expression of the COL7A1 gene, as exempli®ed by the dystrophic forms of epidermolysis bullosa (reviewed by Uitto and Christiano, 1998) . It may therefore be speculated that an adaptive phenomenon has taken place, allowing activation of COL7A1 gene expression in response to a variety of stimuli, including those by pro-in¯ammatory cytokines.
We have previously demonstrated that cytokine responsiveness of the COL7A1 gene was altered as a function of the age of the tissue donor (Chen et al., 1994a) . Speci®cally, TGF-b was shown to consistently enhance COL7A1 gene expression, independent from the donor's age, whereas the upregulation by TNF-a or IL-1b was signi®cantly higher in cells from younger donors, suggesting that in the case of these inflammatory cytokines, similar regulatory mechanisms may be involved. In this study, we have identi®ed NF-kB as the transcription factor mediating the eect of TNF-a on COL7A1 promoter activity, whereas TGF-b eect requires the involvement of the SMAD signaling pathway (Vindevoghel et al., 1998a,b) . Interestingly, NF-kB has been shown to mediate several of the biological functions of both TNF-a and IL-1 (reviewed in Siebenlist et al., 1994) , whereas the SMAD pathway appears to be speci®c for the TGF-b family members (reviewed in MassagueÂ , 1996; Baker and Harland, 1997; Heldin et al., 1997) . At the present time, it is unclear whether the previously described alterations of COL7A1 gene expression as a function of the age of the skin donor are related to an alteration in NF-kBmediated transcription. Our previous studies may indeed support this hypothesis, as we have previously demonstrated that both type I collagen (COL1A2) and interstitial collagenase gene responses to IL-1 and TNF-a are reduced at the transcriptional level as a function of the age of the skin donor (Chen et al., 1994b) . Recently, we have identi®ed NF-kB as a key factor for TNF-a-mediated inhibition of COL1A2 gene expression , and other investigators have shown that cultured ®broblasts in senescence After glycerol shock, the cultures were incubated in fresh medium containing 1% fetal calf serum for 4 h, prior to TNF-a and/or TGF-b addition (10 ng/ml). Cell extracts were assayed for CAT activity with [ 14 C]chloramphenicol as a substrate, using identical amounts of protein. The ®gure shows a representative autoradiogram of each CAT assay, together with the quantitation (mean+s.d.) of three independent experiments. Note that the relative activities of the dierent constructs should not be compared, as each one of them was assayed with dierent protein amounts in order to optimally assess their respective growth factor responsiveness exhibit lower NF-kB-mediated transcriptional activity (Helenius et al., 1996) . Similarly, lowered induction of NF-kB in human activated T lymphocytes was noted during aging (Trebilcock and Ponnappan, 1996) . These data may be correlated with the loss of rapid tissue repair and reduced anchoring ®bril formation in the elderly during wound healing (Woodley et al., 1990) .
In conclusion, our data provide an in depth analysis of the transcriptional mechanisms regulating COL7A1 gene expression and their modulation by cytokines and growth factors. To our knowledge, this is the ®rst demonstration of additive transcriptional response of a gene to the two immediate-early transcription factors, SMAD and NF-kB.
Materials and methods
Cell cultures
Human dermal ®broblast cultures, established by explanting tissue specimens obtained from neonatal foreskins, were utilized in passages 3 ± 6. Cells were grown in Dulbecco's modi®ed Eagle's medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM glutamine, and antibiotics (100 units/ml penicillin, 50 mg/ ml streptomycin-G and 0.25 mg/ml Fungizone TM ). Human recombinant TGF-b2 was a kind gift from Dr David Olsen, Celtrix Co., (Palo Alto, CA, USA). Human recombinant TNF-a was purchased from Boehringer Mannheim, (Indianapolis, IN, USA).
Plasmid constructs
Various COL7A1 promoter 5' deletion/CAT constructs were cloned into promoterless pBS0CAT vector . Cloning of wild-type and mutant COL7A1 SMAD binding sequence (SBS) and NF-kB fragments into pBLCAT5 was performed according to standard protocols (Sambrook et al., 1989) . The NF-kB1 and RelA expression vectors were obtained through the AIDS Research and Reference Reagent Program, NIAID, NIH: pRSV-NF-kB1 (p50) and pRSV-RelA (p65) from Dr Gary Nabel and Dr Neil Perkins (Duckett et al., 1993) .
Transient cell transfections and CAT assays
Transient cell transfections of human dermal ®broblasts were performed with calcium phosphate/DNA co-precipitation procedure (Graham and Van der Eb, 1973) . Following appropriate incubation periods (see Figure  legends) , the cells were rinsed once with phosphate buered saline, harvested by scraping and lysed in 200 ml of Reporter Lysis Buer (Promega, Madison, WI, USA). The b-galactosidase activities were measured according to a standard protocol (Sambrook et al., 1989) . Unless stated otherwise, aliquots corresponding to identical b-galactosidase activity were used for each CAT assay with [ 14 C]chloramphenicol as substrate (Gorman et al., 1982) , using thin layer chromatography. Following autoradiography, the plates were cut and counted by liquid scintillation to quantify the acetylated [
14 C]chloramphenicol.
Electrophoresis mobility shift assays
Promoter fragments spanning distinct regions of the COL7A1 promoter were generated by PCR ampli®cation using 7722COL7A1/CAT as template, or by using annealed synthetic oligonucleotides, radiolabeled, and puri®ed by electro-elution after electrophoresis in a 2% agarose gel, as described previously . Nuclear extracts were isolated using a small scale preparation (Andrew and Faller, 1991) , aliquoted in small fractions to avoid repetitive freeze-thawing, and stored at 7808C until use. The protein concentration in the extracts was determined using a commercial assay kit (Bio-Rad).
For supershift experiments, the following antibodies were used: rabbit polyclonal antibodies against NF-kB1 and RelA , NF-kB2 (p52) (Lanoix et al., 1994) , Rel (p75) (Tan et al., 1992) , RelB (p68) (Nancy Rice, unpublished; raised against a synthetic 17-amino acid peptide covering the C-terminus of human RelB: RE-AAFGGGLLPGPEAT), a pan-NF-AT antibody, raised against an internal peptide of human NF-AT common to all members of the NF-AT family (Lyakh et al., 1997) . Nuclear extracts were incubated overnight with 1 ml of either antisera prior to the binding reaction.
